Roche's Genentech Breaks Ground on North Carolina Manufacturing Site

Dow Jones

2025/08/26

By Katherine Hamilton

Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina.

The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast.

The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said.

The facility is scheduled to be completed and operational by 2029.

The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

August 25, 2025 14:58 ET (18:58 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562922478"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562922478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562922478?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 02:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562922478","market":"sh","top_or_hot":-1,"title":"Roche's Genentech Breaks Ground on North Carolina Manufacturing Site","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina. \n</p>\n<p>\n  The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast. \n</p>\n<p>\n  The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said. \n</p>\n<p>\n  The facility is scheduled to be completed and operational by 2029. \n</p>\n<p>\n  The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 25, 2025 14:58 ET (18:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Genentech Breaks Ground on North Carolina Manufacturing Site</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Genentech Breaks Ground on North Carolina Manufacturing Site\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-26 02:58</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina. \n</p>\n<p>\n  The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast. \n</p>\n<p>\n  The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said. \n</p>\n<p>\n  The facility is scheduled to be completed and operational by 2029. \n</p>\n<p>\n  The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 25, 2025 14:58 ET (18:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CARO","symbol_name":"Carolina Financial Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562922478","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562922478","pubTimestamp":1756148280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina.The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast.The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said.The facility is scheduled to be completed and operational by 2029.The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CARO":"Carolina Financial Corporation","RHHBY":"罗氏控股","BK4007":"制药","03165":"华夏欧优股对冲"},"translate_title":"罗氏基因泰克在北卡罗来纳州生产基地破土动工","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9,"CARO":1},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina. \n\n\n  The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast. \n\n\n  The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said. \n\n\n  The facility is scheduled to be completed and operational by 2029. \n\n\n  The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 25, 2025 14:58 ET (18:58 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}